BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Larsen CP, Wilson JD, Best-Rocha A, Beggs ML, Hennigar RA. Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy. Mod Pathol 2018;31:488-94. [PMID: 29148534 DOI: 10.1038/modpathol.2017.154] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 El Karoui K, Boudhabhay I, Petitprez F, Vieira-Martins P, Fakhouri F, Zuber J, Aulagnon F, Matignon M, Rondeau E, Mesnard L, Halimi JM, Frémeaux-Bacchi V. Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. Haematologica 2019;104:2501-11. [PMID: 30890598 DOI: 10.3324/haematol.2019.216903] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
2 Ding J, Qu Z, Yu F. A rare case of malignant hypertension with splenic rupture and thrombotic microangiopathy: A case report. Medicine (Baltimore) 2020;99:e20581. [PMID: 32664062 DOI: 10.1097/MD.0000000000020581] [Reference Citation Analysis]
3 Tsai HM. Atypical Hemolytic Uremic Syndrome: Beyond Hemolysis and Uremia. Am J Med 2019;132:161-7. [PMID: 30145224 DOI: 10.1016/j.amjmed.2018.08.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
4 Menendez-Castro C, Cordasic N, Fahlbusch FB, Ekici AB, Kirchner P, Daniel C, Amann K, Velkeen R, Wölfle J, Schiffer M, Hartner A, Hilgers KF. RNA sequencing reveals induction of specific renal inflammatory pathways in a rat model of malignant hypertension. J Mol Med (Berl) 2021;99:1727-40. [PMID: 34528115 DOI: 10.1007/s00109-021-02133-8] [Reference Citation Analysis]
5 Cavero T, Arjona E, Soto K, Caravaca-fontán F, Rabasco C, Bravo L, de la Cerda F, Martín N, Blasco M, Ávila A, Huerta A, Cabello V, Jarque A, Alcázar C, Fulladosa X, Carbayo J, Anaya S, Cobelo C, Ramos N, Iglesias E, Baltar J, Martínez-gallardo R, Pérez L, Morales E, González R, Macía M, Draibe J, Pallardó L, Quintana LF, Espinosa M, Barros X, Pereira F, Cao M, Moreno JA, Rodríguez de Córdoba S, Praga M. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. Kidney International 2019;96:995-1004. [DOI: 10.1016/j.kint.2019.05.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
6 Zhang Y, Yang C, Zhou X, Hu R, Quan S, Zhou Y, Li Y, Xing G. Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis. Nephrol Dial Transplant 2020:gfaa280. [PMID: 33367879 DOI: 10.1093/ndt/gfaa280] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Zuckerman JE, Chang A. Complement and Renal Thrombotic Microangiopathy Associated With Hypertension and Scleroderma. Adv Chronic Kidney Dis 2020;27:149-54. [PMID: 32553247 DOI: 10.1053/j.ackd.2019.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Iba T, Watanabe E, Umemura Y, Wada T, Hayashida K, Kushimoto S, Wada H; Japanese Surviving Sepsis Campaign Guideline Working Group for disseminated intravascular coagulation. Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. J Intensive Care 2019;7:32. [PMID: 31139417 DOI: 10.1186/s40560-019-0387-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
9 Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 2021;17:543-53. [PMID: 33953366 DOI: 10.1038/s41581-021-00424-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Iba T, Levy JH, Wada H, Thachil J, Warkentin TE, Levi M; Subcommittee on Disseminated Intravascular Coagulation. Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. J Thromb Haemost 2019;17:415-9. [PMID: 30618150 DOI: 10.1111/jth.14354] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
11 Timmermans SAMEG, van Paassen P; Limburg Renal Registry. Mother and Child Reunion in "Hypertensive" End-Stage Renal Disease: Will They Complement Each Other? Nephron 2019;142:253-7. [PMID: 30870849 DOI: 10.1159/000497779] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hanna RM, Barsoum M, Vandross A, Kurtz I, Burwick R. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition. Curr Opin Nephrol Hypertens 2019;28:278-87. [PMID: 30865166 DOI: 10.1097/MNH.0000000000000499] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
13 Haydock L, Garneau AP, Tremblay L, Yen HY, Gao H, Harrisson R, Isenring P. Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy. J Mol Med (Berl) 2021. [PMID: 34714369 DOI: 10.1007/s00109-021-02102-1] [Reference Citation Analysis]
14 Schönauer R, Seidel A, Grohmann M, Lindner TH, Bergmann C, Halbritter J. Deleterious Impact of a Novel CFH Splice Site Variant in Atypical Hemolytic Uremic Syndrome. Front Genet 2019;10:465. [PMID: 31156713 DOI: 10.3389/fgene.2019.00465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Wenzel UO, Kemper C, Bode M. The role of complement in arterial hypertension and hypertensive end organ damage. Br J Pharmacol 2021;178:2849-62. [PMID: 32585035 DOI: 10.1111/bph.15171] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Timmermans SAMEG, Wérion A, Damoiseaux JGMC, Morelle J, Reutelingsperger CP, van Paassen P. Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy. Hypertension 2020;75:422-30. [PMID: 31865800 DOI: 10.1161/HYPERTENSIONAHA.119.13714] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]